Clinical trials Below are current clinical trials.67 studies in Nephrology and Hypertension (open studies only). Filter this list of studies by location, status and more. Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND) Jacksonville, Fla. The purpose of this multi-center event-driven study in non-dialysis (ND) participants with anemia associated with chronic kidney disease (CKD) is to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa. Authorizaton to Use Clincially Obtained Data for Research Rochester, Minn. This study is being done to gather information regarding your health in relation to your composite tissue transplant. We would like to use your medical records (both existing and future) to study the health of patients who will receive or have received a composite tissue transplant. This research would include looking at your demographic information, cause of initial injury, laboratory test results and medical exams relating to your pre and post transplant care, and your mental well-being before and after transplant. HELP-HY: Health Education and sLeep Program in HYpertension Rochester, Minn. Hypertension is the major risk factor for cardiovascular and cerebrovascular diseases worldwide. The escalating prevalence of inadequate sleep now parallels that of hypertension. Observational and experimental evidence favoring a causal relation between insufficient sleep and hypertension are particularly compelling - sleeping 6 hours or less per night is associated with a 20-32% higher probability of incident hypertension. Since sleep curtailment is largely voluntary, sleep deficiency may be corrected and the detrimental health consequences potentially reversed. In this study the investigators aim to investigate the effects of 8 weeks of sleep enhancement/extension vs health education in prehypertensive and stage 1 hypertensive subjects who report habitual short sleep (=6.5 hours/night). Statins and CPAP in Adipose Tissue of OSA Rochester, Minn. This study is aimed at examining the alterations in adipose tissue in obstructive sleep apnea (OSA) patients in response to treatment with atorvastatin in continuation with standard treatment with continuous positive airway pressure (CPAP). Post Approval Study for Treatment of Drug-resistant Adult Primary FSGS Using the LIPOSORBER® LA-15 System Rochester, Minn. The purpose of this study is to evaluate the probable benefit and safety of the LIPOSORBER® LA-15 System for the treatment of adult patients with nephrotic syndrome associated with primary focal segmental glomerulosclerosis, when the standard treatment options, including corticosteroid and/or calcineurin inhibitors treatments, have been unsuccessful or not well tolerated, and the patient has a GFR ≥ 60 ml/min/1.73m2, or the patient has post-renal transplant recurrence. Treatment for FSGS is considered unsuccessful if the patient is unresponsive to standard therapy (e.g., at least 8 weeks of corticosteroids) and fails to achieve complete or partial remission. A standard treatment is considered not well tolerated if the patient experiences severe side effects without providing an acceptable level of clinical benefit. Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease Rochester, Minn. As the global epidemic of obesity and diabetes mellitus spreads, an exponential rise in incident chronic kidney disease (CKD) complicated by end stage renal disease (ESRD) is predicted, leaving healthcare systems overwhelmed worldwide. Hence, there is urgent need for novel therapies to slow the progression of DKD and optimize the health of this patient population. The purpose of this study is to examine the effect of a supplement on mesenchymal stem cells, physical body function (or frailty), kidney function, and total clearance of senescent cells in individuals with CKD. At present, we are enrolling participants with CKD, with a subset of participants with diabetic kidney disease (DKD), aged 40-80 years, and eGFR 15-60 mL/min/1.73m2. After screening and enrollment, study participants will be randomized to either the treatment or non-treatment (placebo) arm. Participants in the treatment arm will take the supplement drug for 2 days. For all participants, an olive-sized sample of subcutaneous fat will be taken from the abdomen for MSC isolation and repeated at day 14. A frailty assessment along with blood and urine laboratory testing will be done at a total of 3 study visits (enrollment, day 14, and month 4). Mail-out labs will be accepted for month 12 follow-up. Rare Kidney Stone Consortium Patient Registry Rochester, Minn., Jacksonville, Fla. The purpose of this study is to collect medical information from a large number of patients in many areas of the world with primary hyperoxaluria (PH), Dent disease, Cystinuria and APRT deficiency. This information will create a registry that will help us to compare similarities and differences in patients and their symptoms. The more patients we are able to enter into the registry, the more we will be able to understand the Primary Hyperoxalurias,Dent disease, cystinuria and APRT and learn better ways of caring for patients with these diseases. Biobank Protocol, Rare Diseases Clinical Research Network Rochester, Minn. This study is being done to obtain samples from patients with primary hyperoxaluria, cystinuria, adenine phosphoribosyl transferase (APRT) deficiency, and Dent disease, and from their family members, for use in future research. Senescence in Chronic Kidney Disease Rochester, Minn. Trials applying stem cells for the treatment of diabetic kidney disease (DKD) will soon be under way. Autologous (from the patient) over allogeneic transplantation is the preferred option. However, success with cellular therapy in DKD patients may be limited by a frailty phenotype and “unhealthy” stem cells due to cellular senescence. The purpose of this study is to examine the effect of two drugs on mesenchymal stem cells, physical body function (or frailty), kidney function, and total clearance of senescent cells. Information from these investigations will help design preconditioning protocols for clinical trials applying stem cells for the treatment of DKD. At present, we are enrolling participants with DKD, aged 40-80 years, and eGFR 15-45 mL/min/1.73m2. After screening and enrollment, study participants will be randomized to either the treatment or non-treatment (placebo) arm. Participants in the treatment arm will take 2 drugs for 3 days. For all participants, an olive-sized sample of subcutaneous fat will be taken from the abdomen for MSC isolation and repeated at day 14. A frailty assessment along with blood and urine laboratory testing will be done at a total of 3 study visits (enrollment, day 14, and month 4). Mail-out labs will be accepted for month 12 follow-up. Evaluating Stem Cell Function in Patients with Chronic Kidney Disease (CKD) Rochester, Minn. New treatments of the future may use stem cells, cells that naturally occur in our blood or belly/abdominal fat, to help people with kidney disease. The purpose of this study is to understand the function of specific cell types and how well they may work to repair our kidneys. Two cell groups, mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPCs), will be examined. Study participants will include individuals with varying degrees of kidney function and potential causes of kidney disease. This information will help plan for future studies using stem cells to treat kidney disease. Pagination Clinical studies PrevPrevious Page Go to page 22 Go to page 33 Go to page 44 Go to page 55 Go to page 66 NextNext Page Request an Appointment at Mayo Clinic Locations, travel & lodgingResearch Oct. 06, 2020 Share on: FacebookTwitter Nephrology and HypertensionSectionsRequest an appointmentOverviewTests & proceduresConditions treatedDoctorsSpecialty groupsExpertise & rankingsLocations, travel & lodgingClinical trialsResearchCosts & insuranceNews from Mayo ClinicResources for medical professionals Research: It's All About Patients SectionsRequest an appointmentOverviewTests & proceduresConditions treatedDoctorsSpecialty groupsExpertise & rankingsLocations, travel & lodgingClinical trialsResearchCosts & insuranceNews from Mayo ClinicResources for medical professionals ORG-20464466 Departments & Centers Medical Departments & Centers Nephrology and Hypertension